apl-5125
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2024 (NCT06399757)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenocarcinoma · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- UnclearINHIBITOR
Unclear inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06399757 | Phase 1/Phase 2 (Phase 2) | Jun 18, 2024 | Apollo Therapeutics Ltd |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Apollo Therapeutics Ltd | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1